Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein mab-21-like 2 (MAB21L2) is a member of the male-abnormal 21-like (MAB21L) protein family implicated in vertebrate embryonic development, notably in eye formation, neural tube development, and axis specification[2][3]. The protein localizes primarily to the nucleus, where it acts as a transcriptional repressor, physically interacting with SMAD1 and modulating the TGF-β/BMP4 signaling pathways during development[3]. Pathogenic variants in the *MAB21L2* gene cause a spectrum of ocular developmental defects including microphthalmia, anophthalmia, and coloboma, and can result in syndromic malformations (e.g., MCOPS14)[2]. While structurally related to nucleotidyltransferases, MAB21L2’s enzymatic activity remains unproven; evidence supports a role in transcriptional regulation rather than classical enzyme activity[2][3]. Several protein partners, including heat shock proteins (HSPA5, HSPA8), have been identified as interactors, potentially impacting protein homeostasis in normal and mutant states[2]. There are currently no therapeutic drugs targeting MAB21L2, and its main disease relevance is as a cause of developmental syndromes.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein mab-21-like 2 (MAB21L2).